諾和諾德將於 ObesityWeek 2026 發表肥胖症產品組合的最新數據
諾和諾德表示，將在 ObesityWeek 2026 發表 26 篇摘要，內容包括其肥胖症治療產品線的新數據，以及 Wegovy 的真實世界使用經驗。
prnewswire.com ·
支援資產
開啟 Mo
Novo Nordisk
24/7
-
-所選期間
-相較美股收盤
新聞
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
BioSpace reports Eli Lilly's retatrutide beat Novo Nordisk's Ozempic in weight loss and blood sugar reduction in a trial, with a regulatory application expected in the first quarter of 2027.
biospace.com ·
Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)
Benzinga reports Novo Nordisk failed in its court bid to block Eli Lilly's weight-loss drug ads, with the judge finding little evidence of market impact or lasting harm.
benzinga.com ·
Novo Nordisk to Present New Semaglutide Clinical Data at The Liver Meeting 2026
Novo Nordisk announced it will present 12 new abstracts of real-world and clinical semaglutide data at the AASLD Liver Meeting in November 2026.
prnewswire.com ·
禮來的 retatrutide 在後期試驗中勝過諾和諾德的 Ozempic | $NVO $LLY $NONOF $NOW
Seeking Alpha 報導，禮來的實驗性肥胖藥 retatrutide 在後期臨床試驗中勝過諾和諾德的 Ozempic。
seekingalpha.com ·
代幣
- 代幣
- NVOc
- 每枚代幣對應股數
- 1.00000000 NVO
取得 Mo
在 Mo 中持有
將 NVOc 存放在你自行掌控的 Base 上 Mo 智慧錢包中。
快速轉移
免費將 NVOc 發送給其他 Mo 使用者，或以極快速度轉移至任何相容的 Base 錢包。